The benefits of upadacitinib need to be weighed against individual patients' risk profiles, but the drug is an important step forward in treating Crohn disease, an ACP Journal Club commentary said.
22 Sep 2023
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
Given their overall safety and convenience, etrasimod and other oral sphingosine-1-phosphate receptor modulators can be considered as first-line therapy in clinically appropriate patients with ulcerative colitis (UC) who do not respond to 5-aminosalicylic acid medications, an ACP Journal Club commentary said.
28 Jul 2023
Findings of the randomized trial bolster recommendations of diet manipulation and lifestyle modifications for chronic constipation syndromes, an ACP Journal Club commentary said.
26 May 2023
In H pylori infection, vonoprazan plus high-dose amoxicillin was noninferior to B-quadruple therapy for eradication
While the dual therapy provides another promising option for Helicobacter pylori eradication, replicating the findings in more diverse patient populations would provide additional reassurance about widespread use, an ACP Journal Club commentary noted.
26 May 2023
In older patients receiving aspirin, H pylori eradication reduced hospitalization or death due to peptic ulcer bleeding at 2.5 y
Several limitations of the trial may affect the extent to which the results will change current practice of Helicobacter pylori eradication in patients receiving aspirin, especially older patients, an ACP Journal Club commentary noted.
21 Apr 2023
In adults receiving mechanical ventilation, selective decontamination of the digestive tract reduces hospital mortality
While findings of the meta-analysis did not show evidence of increased incidence of antimicrobial-resistant organisms, the review included data from regions that have very low levels of antimicrobial resistance, an ACP Journal Club commentary noted.
24 Mar 2023
JAK inhibitors, such as upadacitinib, represent an advance in the management of patients with ulcerative colitis (UC); however, it remains unclear whether the balance of efficacy versus risk favors one drug over the others, according to an ACP Journal Club commentary.
28 Oct 2022
The recommendations from the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG), particularly those for withholding antithrombotics before planned endoscopic procedures, require individualized decision making with multidisciplinary input, an ACP Journal Club commentary said.
22 Jul 2022
While the FDA has now approved risankizumab for adults with moderate to severe Crohn disease, understanding of the drug's role in relation to other biologic therapies is limited by broad exclusion criteria in randomized controlled trials, an ACP Journal Club commentary noted.
28 Oct 2022
In adults using oral anticoagulants, PPI use may be associated with lower risk for upper GI bleeding
An ACP Journal Club commentary on the meta-analysis stressed the importance of assessing patients' underlying risk for GI bleeding and using overall clinical risk to guide shared decision making in those at higher risk or with lower baseline bleeding tolerance.
18 Nov 2022